临床试验

A Study of Mosliciguat in PH-ILD

NCT：NCT06635850 · ACTIVE_NOT_RECRUITING

NCT编号NCT06635850

状态ACTIVE_NOT_RECRUITING

开始日期2024-10-29

SponsorPulmovant, Inc. (INDUSTRY)

First posted2024-10-10

Last updated2026-09-10

简要摘要

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态，请参阅官方记录。